Rigel Pharma (RIGL)
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer i...
- Open
- 41.370
- High
- 42.040
- Low
- 40.950
- Prev. Close
- 41.660
- Volume
- 208.25K
- Turnover
- 8.69M
- Avg Price
- 41.712
- Bid/Ask Ratio
- -80.00%
- Amplitude
- 2.62%
- 52wk High
- 52.240
- Volume Ratio
- 0.31
- Turnover Ratio
- 1.38%
Rigel Pharma Analyst Rating
View moreForecast & Rating
Aug 5, 2026Price forecast
$55.6032.32%
Forecast & RatingBuy
5analysts
- Strong buy60.00%
- Buy0.00%
- Hold40.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 8 at 04:04 AM
Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL
- PUBT · Aug 7 at 07:04 AM
Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology
- Market Beat · Aug 6 at 02:44 AM
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL
- Tip Ranks · Aug 5 at 08:46 AM
Rigel: Buy Rating Reaffirmed as Solid Commercial Performance and Pipeline Catalysts Support Unchanged $57 Price Target
- TradingKey · Aug 5 at 02:02 AM
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
- Market Beat · Aug 4 at 07:26 PM
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS
